{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T05:08:01Z","timestamp":1794460081322,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Subcutaneous foslevodopa\/foscarbidopa (LDp\/CDp) infusion is approved for treating motor fluctuations and dyskinesias in patients with advanced Parkinson\u2019s disease (aPD). However, efficacy data on non-motor symptoms (NMS) are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the effects of LDp\/CDp treatment on NMS in patients with aPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective analysis of efficacy of LDp\/CDp on NMS after 3\u00a0week therapy in a Parkinson\u2019s day-clinic setting and further 6\u00a0weeks of outpatient treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty-one patients with aPD were assessed at baseline (T0), after 3\u00a0weeks (T1), and after 9 weeks (T2). Assessments included broader NMS according to MDS-UPDRS Part I and NMS questionnaire (NMSQ) and in more detail sleep (PDSS-2) and depression (BDI-2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean MDS-UPDRS I total score significantly improved by 27% at T1 and 34% at T2 (3.90 and 4.85 points, respectively), which has to be considered clinically relevant (threshold -2.64 points). Relevant improvement accounted for 62% of patients at T1 and 57% at T2.<\/jats:p>\n                    <jats:p>MDS-UPDRS part IB score also improved significantly at both timepoints by approximately 30%. The greatest benefits were observed in sleep disturbances, pain, and constipation. NMSQ score improved by 21% at T1 and 27% at T2, particularly within the gastrointestinal domain. PDSS-2 score improved by 27% at T1, and Beck Depression Inventory 2 score by 37% at T1; both showed numerical but non-significant trends at T2. Psychotic symptoms occurred as adverse effects in 4 of 21 patients (19%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this exploratory retrospective cohort, LDp\/CDp therapy improved clinically relevant NMS, though confirmation in larger controlled studies is needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-026-13890-2","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T17:31:16Z","timestamp":1780939876000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of subcutaneous foslevodopa\/foscarbidopa therapy on non-motor symptoms in advanced PD patients"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5772-1938","authenticated-orcid":false,"given":"Alina","family":"Jander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5165-3868","authenticated-orcid":false,"given":"Sarah","family":"Bergner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Sch\u00f6nwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7680-2147","authenticated-orcid":false,"given":"Monika","family":"P\u00f6tter-Nerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8540-3789","authenticated-orcid":false,"given":"Carsten","family":"Buhmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8016-1821","authenticated-orcid":false,"given":"Ute","family":"Hidding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"13890_CR1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/s0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 386:896\u2013912. https:\/\/doi.org\/10.1016\/s0140-6736(14)61393-3","journal-title":"Lancet"},{"issue":"7","key":"13890_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.62","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira AHV, Chaudhuri KR, Jenner P (2017) Non-motor features of Parkinson disease. Nat Rev Neurosci 18(7):435\u2013450. https:\/\/doi.org\/10.1038\/nrn.2017.62","journal-title":"Nat Rev Neurosci"},{"key":"13890_CR3","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00702-017-1757-0","volume":"124","author":"J Classen","year":"2017","unstructured":"Classen J, Koschel J, Oehlwein C et al (2017) Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues. J Neural Transm 124:1029\u20131036. https:\/\/doi.org\/10.1007\/s00702-017-1757-0","journal-title":"J Neural Transm"},{"key":"13890_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/rlu.0000000000001470","volume":"42","author":"A Bestetti","year":"2017","unstructured":"Bestetti A, Capozza A, Lacerenza M et al (2017) Delayed gastric emptying in advanced Parkinson disease: correlation with therapeutic doses. Clin Nucl Med 42:83\u201387. https:\/\/doi.org\/10.1097\/rlu.0000000000001470","journal-title":"Clin Nucl Med"},{"key":"13890_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1757","volume":"10","author":"WA Kamel","year":"2020","unstructured":"Kamel WA, Al-Hashel JY (2020) LCIG in treatment of non-motor symptoms in advanced Parkinson\u2019s disease: review of literature. Brain Behav 10:e01757. https:\/\/doi.org\/10.1002\/brb3.1757","journal-title":"Brain Behav"},{"key":"13890_CR6","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/mds.28595","volume":"36","author":"T Tsunemi","year":"2021","unstructured":"Tsunemi T, Oyama G, Saiki S et al (2021) Intrajejunal infusion of levodopa\/carbidopa for advanced Parkinson\u2019s disease: a systematic review. Mov Disord 36:1759\u20131771. https:\/\/doi.org\/10.1002\/mds.28595","journal-title":"Mov Disord"},{"issue":"1","key":"13890_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/ana.26073","volume":"90","author":"M Rosebraugh","year":"2021","unstructured":"Rosebraugh M, Voight EA, Moussa EM et al (2021) Foslevodopa\/Foscarbidopa: a new subcutaneous treatment for Parkinson\u2019s disease. Ann Neurol 90(1):52\u201361. https:\/\/doi.org\/10.1002\/ana.26073","journal-title":"Ann Neurol"},{"key":"13890_CR8","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/mdc3.14018","volume":"11","author":"KR Chaudhuri","year":"2024","unstructured":"Chaudhuri KR, Facheris MF, Bergmans B et al (2024) Improved sleep correlates with improved quality of life and motor symptoms with foslevodopa\/foscarbidopa. Mov Disord Clin Pract 11:861\u2013866. https:\/\/doi.org\/10.1002\/mdc3.14018","journal-title":"Mov Disord Clin Pract"},{"key":"13890_CR9","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/s1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K et al (2022) Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21:1099\u20131109. https:\/\/doi.org\/10.1016\/s1474-4422(22)00400-8","journal-title":"Lancet Neurol"},{"key":"13890_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2025.100330","volume":"12","author":"KR Chaudhuri","year":"2025","unstructured":"Chaudhuri KR, Bouchard M, Freire-Alvarez E et al (2025) Post hoc exploratory analysis of the effect of foslevodopa\/foscarbidopa continuous subcutaneous infusion on nocturia in patients with Parkinson\u2019s disease. Clin Parkinsonism Relat Disord 12:100330. https:\/\/doi.org\/10.1016\/j.prdoa.2025.100330","journal-title":"Clin Parkinsonism Relat Disord"},{"issue":"6","key":"13890_CR11","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred J, Freire-Alvarez E, Amelin AV et al (2023) Continuous subcutaneous Foslevodopa\/Foscarbidopa in Parkinson\u2019s Disease: safety and efficacy results from a 12-month, single-arm, open-label, Phase 3 study. Neurol Ther 12(6):1937\u20131958. https:\/\/doi.org\/10.1007\/s40120-023-00533-1","journal-title":"Neurol Ther"},{"key":"13890_CR12","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s00702-018-1918-9","volume":"125","author":"O Fr\u00fcndt","year":"2018","unstructured":"Fr\u00fcndt O, Mainka T, Sch\u00f6nwald B et al (2018) The Hamburg Parkinson day-clinic: a new treatment concept at the border of in- and outpatient care. J Neural Transm 125:1461\u20131472. https:\/\/doi.org\/10.1007\/s00702-018-1918-9. (20180822.)","journal-title":"J Neural Transm"},{"key":"13890_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2025.1619850","volume":"17","author":"A Jander","year":"2025","unstructured":"Jander A, Bergner S, Sch\u00f6nwald B et al (2025) Subcutaneous foslevodopa\/foscarbidopa initiation in a Parkinson\u2019s day-clinic\u2014a suitable setting to ensure treatment efficacy, tolerability and psychosocial adaption. Front Aging Neurosci 17:1619850. https:\/\/doi.org\/10.3389\/fnagi.2025.1619850. (20250910.)","journal-title":"Front Aging Neurosci"},{"key":"13890_CR14","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement disorder society-sponsored revision of the Unified Parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129\u20132170. https:\/\/doi.org\/10.1002\/mds.22340","journal-title":"Mov Disord"},{"key":"13890_CR15","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/mds.20844","volume":"21","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri KR, Martinez-Martin P, Schapira AH et al (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson\u2019s disease: the NMSQuest study. Mov Disord 21:916\u2013923. https:\/\/doi.org\/10.1002\/mds.20844","journal-title":"Mov Disord"},{"key":"13890_CR16","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/mds.23476","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kohnen R, H\u00f6gl B et al (2011) Parkinson\u2019s disease sleep scale--validation of the revised version PDSS-2. Mov Disord 26:644\u2013652. https:\/\/doi.org\/10.1002\/mds.23476. (20110210.)","journal-title":"Mov Disord"},{"key":"13890_CR17","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mds.20792","volume":"21","author":"M Visser","year":"2006","unstructured":"Visser M, Leentjens AF, Marinus J et al (2006) Reliability and validity of the beck depression inventory in patients with Parkinson\u2019s disease. Mov Disord 21:668\u2013672. https:\/\/doi.org\/10.1002\/mds.20792","journal-title":"Mov Disord"},{"key":"13890_CR18","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/mds.26960","volume":"32","author":"K Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th K, Aschermann Z, Kov\u00e1cs M et al (2017) Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored Unified Parkinson\u2019s disease rating scale. Mov Disord 32:789\u2013793. https:\/\/doi.org\/10.1002\/mds.26960. (20170220.)","journal-title":"Mov Disord"},{"key":"13890_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-025-02911-5","author":"T Koeglsperger","year":"2025","unstructured":"Koeglsperger T, Berberovic E, Dresel C et al (2025) Real-world experience with continuous subcutaneous foslevodopa\/foscarbidopa infusion: insights and recommendations. J Neural Transm. https:\/\/doi.org\/10.1007\/s00702-025-02911-5","journal-title":"J Neural Transm"},{"issue":"1","key":"13890_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14802\/jmd.24227","volume":"18","author":"I Boura","year":"2025","unstructured":"Boura I, Poplawska-Domaszewicz K, Spanaki C et al (2025) Non-motor fluctuations in Parkinson\u2019s disease: underdiagnosed yet important. J Mov Disord 18(1):1\u201316. https:\/\/doi.org\/10.14802\/jmd.24227","journal-title":"J Mov Disord"},{"key":"13890_CR21","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/bs.irn.2017.05.036","volume":"134","author":"U Mundt-Petersen","year":"2017","unstructured":"Mundt-Petersen U, Odin P (2017) Infusional therapies, continuous dopaminergic stimulation, and nonmotor symptoms. Int Rev Neurobiol 134:1019\u20131044. https:\/\/doi.org\/10.1016\/bs.irn.2017.05.036. (20170724.)","journal-title":"Int Rev Neurobiol"},{"key":"13890_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/nss.S78947","volume":"8","author":"SM Abbott","year":"2016","unstructured":"Abbott SM, Videnovic A (2016) Chronic sleep disturbance and neural injury: links to neurodegenerative disease. Nat Sci Sleep 8:55\u201361. https:\/\/doi.org\/10.2147\/nss.S78947","journal-title":"Nat Sci Sleep"},{"key":"13890_CR23","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/s1474-4422(13)70047-4","volume":"12","author":"D Berg","year":"2013","unstructured":"Berg D, Lang AE, Postuma RB et al (2013) Changing the research criteria for the diagnosis of Parkinson\u2019s disease: obstacles and opportunities. Lancet Neurol 12:514\u2013524. https:\/\/doi.org\/10.1016\/s1474-4422(13)70047-4","journal-title":"Lancet Neurol"},{"key":"13890_CR24","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.parkreldis.2014.09.013","volume":"20","author":"A Rizos","year":"2014","unstructured":"Rizos A, Martinez-Martin P, Odin P et al (2014) Characterizing motor and non-motor aspects of early-morning off periods in Parkinson\u2019s disease: an international multicenter study. Parkinsonism Relat Disord 20:1231\u20131235. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.09.013","journal-title":"Parkinsonism Relat Disord"},{"key":"13890_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70060","author":"S Broh\u00e9e","year":"2025","unstructured":"Broh\u00e9e S, Roze E, Grabli D et al (2025) Cognitive and psychiatric adverse effects of foslevodopa\/foscarbidopa in patients with Parkinson\u2019s disease. Mov Disord Clin Pract. https:\/\/doi.org\/10.1002\/mdc3.70060","journal-title":"Mov Disord Clin Pract"},{"key":"13890_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-022-00295-x","volume":"8","author":"T Warnecke","year":"2022","unstructured":"Warnecke T, Sch\u00e4fer KH, Claus I et al (2022) Gastrointestinal involvement in Parkinson\u2019s disease: pathophysiology, diagnosis, and management. npj Parkinsons Dis 8:31. https:\/\/doi.org\/10.1038\/s41531-022-00295-x","journal-title":"npj Parkinsons Dis"},{"key":"13890_CR27","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/mds.22596","volume":"24","author":"H Honig","year":"2009","unstructured":"Honig H, Antonini A, Martinez-Martin P et al (2009) Intrajejunal levodopa infusion in Parkinson\u2019s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24:1468\u20131474. https:\/\/doi.org\/10.1002\/mds.22596","journal-title":"Mov Disord"},{"key":"13890_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.parkreldis.2018.08.010","volume":"55","author":"JT Hinkle","year":"2018","unstructured":"Hinkle JT, Perepezko K, Mills KA et al (2018) Dopamine transporter availability reflects gastrointestinal dysautonomia in early Parkinson disease. Parkinsonism Relat Disord 55:8\u201314. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.08.010","journal-title":"Parkinsonism Relat Disord"},{"key":"13890_CR29","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/ene.15734","volume":"30","author":"V Leta","year":"2023","unstructured":"Leta V, Klingelhoefer L, Longardner K et al (2023) Gastrointestinal barriers to levodopa transport and absorption in Parkinson\u2019s disease. Eur J Neurol 30:1465\u20131480. https:\/\/doi.org\/10.1111\/ene.15734","journal-title":"Eur J Neurol"},{"issue":"2","key":"13890_CR30","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.parkreldis.2014.11.015","volume":"21","author":"G Pagano","year":"2015","unstructured":"Pagano G, Tan EE, Haider JM et al (2015) Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson\u2019s disease. Parkinsonism Relat Disord 21(2):120\u2013125. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.11.015","journal-title":"Parkinsonism Relat Disord"},{"key":"13890_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-211-45295-0_47","author":"E Wolters","year":"2006","unstructured":"Wolters E, Braak H (2006) Parkinson\u2019s disease: premotor clinico-pathological correlations. J Neural Transm Suppl. https:\/\/doi.org\/10.1007\/978-3-211-45295-0_47","journal-title":"J Neural Transm Suppl"},{"key":"13890_CR32","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1097\/j.pain.0000000000002107","volume":"162","author":"V Mylius","year":"2021","unstructured":"Mylius V, Perez Lloret S, Cury RG et al (2021) The Parkinson disease pain classification system: results from an international mechanism-based classification approach. Pain 162:1201\u20131210. https:\/\/doi.org\/10.1097\/j.pain.0000000000002107","journal-title":"Pain"},{"key":"13890_CR33","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3233\/jpd-240026","volume":"14","author":"A Storch","year":"2024","unstructured":"Storch A, Bremer A, Gandor F et al (2024) Pain fluctuations in Parkinson\u2019s disease and their association with motor and non-motor fluctuations. J Parkinsons Dis 14:1451\u20131468. https:\/\/doi.org\/10.3233\/jpd-240026","journal-title":"J Parkinsons Dis"},{"key":"13890_CR34","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1002\/mds.22546","volume":"24","author":"A Nebe","year":"2009","unstructured":"Nebe A, Ebersbach G (2009) Pain intensity on and off levodopa in patients with Parkinson\u2019s disease. Mov Disord 24:1233\u20131237. https:\/\/doi.org\/10.1002\/mds.22546","journal-title":"Mov Disord"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13890-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13890-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13890-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:22:26Z","timestamp":1783495346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13890-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["13890"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13890-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AJ and SB have no conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Evaluation of treatment was primarily done as part of the clinical routine; second, as an internal quality assurance of the new concept of day-clinic-based medication pump initiation; third, to generate data for internal process optimization; and fourth, because public health insurances demanded certain quality standards and treatment outcomes. Therefore, presented data are not part of a clinical study. According to the local ethics committee of Hamburg, there are no objections to publishing this kind of data (reference number PV5799, WF-028\/18)","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No generative AI was used during the writing process of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI in scientific writing"}}],"article-number":"379"}}